 FSME-Immun (European TBE vaccine) | |
| Vaccine description | |
|---|---|
| Target | Tick-borne encephalitis virus |
| Vaccine type | Inactivated |
| Clinical data | |
| Trade names | Encepur N, FSME-Immun CC, Ticovac, others |
| Routes of administration | Intramuscular |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| KEGG | |
  (what is this?) (verify) | |
Tick-borne encephalitis vaccine is a vaccine used to prevent tick-borne encephalitis (TBE).[4] The disease is most common in Central and Eastern Europe, and Northern Asia.[4] More than 87% of people who receive the vaccine develop immunity.[5] It is not useful following the bite of an infected tick.[4] It is given by injection into a muscle.[4]
The World Health Organization (WHO) recommends immunizing all people in areas where the disease is common.[4] Otherwise the vaccine is just recommended for those who are at high risk.[4] Three doses are recommended followed by additional doses every three to five years.[4] The vaccines can be used in people more than one or three years of age depending on the formulation.[4] The vaccine appears to be safe during pregnancy.[4]
Serious side effects are very uncommon.[4] Minor side effects may include fever, and redness and pain at the site of injection.[4] Older formulations were more commonly associated with side effects.[4]
The first vaccine against TBE was developed in 1937.[4] It is on the World Health Organization's List of Essential Medicines.[6][7] The vaccine was approved for medical use in the United States in August 2021.[2][3][8][9]
- ^ "TicoVac 0.5 ml Suspension for injection in a prefilled syringe - Summary of Product Characteristics (SmPC)". (emc). Retrieved 23 August 2021.
- ^ a b "Ticovac". U.S. Food and Drug Administration (FDA). 16 August 2021. STN: 125740. Retrieved 23 August 2021.
This article incorporates text from this source, which is in the public domain.
- ^ a b "U.S. FDA Approves Ticovac, Pfizer's Tick-Borne Encephalitis (TBE) Vaccine". Pfizer (Press release). Retrieved 23 August 2021.
- ^ a b c d e f g h i j k l m "Vaccines against tick-borne encephalitis: WHO position paper" (PDF). Relevé Épidémiologique Hebdomadaire. 86 (24): 241–256. June 2011. hdl:10665/241769. PMID 21661276.
- ^ Demicheli V, Debalini MG, Rivetti A (January 2009). "Vaccines for preventing tick-borne encephalitis". The Cochrane Database of Systematic Reviews. 2009 (1): CD000977. doi:10.1002/14651858.CD000977.pub2. PMC 6532705. PMID 19160184.
- ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
- ^ "First Tick-Borne Encephalitis Vax Approved in the U.S." 16 August 2021.
- ^ "3: Infectious Diseases Related to Travel". CDC Health Information for International Travel 2016. Oxford University Press. 1 June 2015. ISBN 978-0199379156. Archived from the original on 11 June 2016.
